Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | ​​NRG-HN002: Translational analysis of plasma tumor tissue modified viral HPV DNA and outcomes

Sue S. Yom, MD, PhD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses results from a translational analysis from NRG-HN002 (NCT02254278) evaluating the association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome. Blood samples to be analysed were taken from patients at three points during the trial – at baseline, 2 weeks into treatment, and 2-4 weeks post-treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.